Group 1 - The demand for antiviral drugs has significantly increased due to a rise in flu patients across multiple regions in the country [1] - Sales of various antiviral medications, including Oseltamivir and Mabalaosavir, have surged, with Oseltamivir's sales increasing by 237% and Mabalaosavir's by 180% in the past week [3] - Other medications such as antipyretics, cough suppressants, and nasal sprays have also seen sales increases exceeding 53% [3] Group 2 - In northern cities like Shenyang, Changchun, Xi'an, and Hohhot, the sales of specific flu medications have grown by over 1.5 times [5] - Flu test kits have experienced a tenfold increase in cities such as Beijing, Shenyang, Chengdu, and Xi'an [5] - From November 14 to November 20, the order volume for respiratory bacterial and viral testing increased by 63%, with a positive detection rate rising to 67.7% [7] Group 3 - Patients are opting for home testing services, with results available online within an average of three hours [8] - Despite the rising demand for medications, online pharmacies and brick-and-mortar stores report that drug supplies are sufficient and supply chains are operating smoothly [10]

转自：中国质量报 刚刚过去的9月，扬子江药业集团深入开展第五十四次"质量月"活动。围绕本次"对标世界一流标准，推动企业高质量、可持续发展"活动主题，扬子江药业 集团（以下简称"扬子江"）不仅推出了"全员参与，持续改善，追求卓越""苦练内功，全力以赴，争创更高级别EFQM全球奖"等宣传标语，还举办了一系列 丰富多彩的活动，彰显了这家行业头部药企对质量矢志不渝的坚守，以及追求更好更优发展的目标和信心。 "大质量"全面覆盖 向世界一流标准看齐，扬子江以"大质量"为抓手，不仅重视产品全生命周期质量，更在企业运营质量、数智应用质量、管理质量等方面深耕发力，推动多维 度质量协同升级，成效显著。 产品质量聚焦全生命周期管控，夯实全球竞争硬实力。围绕产品全生命周期质量提升，扬子江通过持续完善药品质量风险管控模式，形成数据驱动、预警及 时、响应快速的药品安全闭环系统，确保每一片药都符合标准要求；通过多品牌矩阵建设与国际标准认证，筑牢产品竞争力根基：打造"扬子江"西药、"龙 凤堂"中药、"护佑"大健康三大品牌，培育出龙凤堂黄芪精、蓝芩口服液等多个10亿元+规模拳头产品；截至9月，累计180余个仿制药品种通过或视同通过质 量和疗效 ...

Core Viewpoint - The Jiangsu Brand Construction Conference emphasizes the importance of brand development for Jiangsu enterprises, with a focus on creating globally influential brands, particularly in the pharmaceutical and health sectors [1][3]. Group 1: Brand Development Strategy - The conference theme "Brand Strong Nation, Su Products First" reflects a collective vision for Jiangsu brands to reach a global audience [3]. - Xu Haoyu, representing Yangtze River Pharmaceutical Group, highlighted the company's brand philosophy, which is closely tied to its mission of "seeking progress and protecting lives" [3][5]. - The company prioritizes quality as the cornerstone of brand building, evidenced by its achievements in quality management and international awards [5]. Group 2: Innovation and Market Strategy - Continuous innovation is essential for meeting the growing health demands of the public, alongside maintaining high quality standards [5]. - In 2024, the company introduced a "Health Marketing, Marketing Health" dual strategy, launching health products that align with modern lifestyles [5]. - The company plans to refresh its brand with new products targeting younger demographics, such as "Little Blue Qing Oral Liquid" and "Little Blue Throat Candy" [5][6]. Group 3: Corporate Responsibility and Community Engagement - Xu emphasized that a strong brand is rooted in responsible corporate behavior, which includes providing safe and effective products and engaging in community welfare [8]. - The company has contributed over 1 billion yuan in various charitable efforts and established 80 standardized planting bases to ensure product quality and support local farmers [8]. - The call for collaboration among Jiangsu enterprises aims to enhance the "Su Products" brand and elevate it from regional strength to global recognition [8]. Group 4: Quality and Innovation as Growth Drivers - The conference highlighted the need for Jiangsu to focus on quality, innovation, ecology, culture, and openness to build strong brands that represent Chinese standards [8]. - The establishment of benchmark brands like Yangtze River Pharmaceutical is seen as crucial for contributing to a brand-strong and quality-strong nation [8].